CA2203085A1 - 5-phosphatase de type ii et son role dans la maladie d'alzheimer - Google Patents

5-phosphatase de type ii et son role dans la maladie d'alzheimer

Info

Publication number: CA2203085A1
Authority: CA; Canada
Prior art keywords: alzheimer; gene; disease; protein; markers
Prior art date: 1997-04-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2203085

Other languages

English (en)

Inventor

Gail Ouellette

Yves Robitaille

Denis Gauvreau

Mario Filion

Magid Belouchi

Isabel Fortier

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

ALGENE BIOTECHNOLOGIES

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-18

Filing date

1997-04-18

Publication date

1998-10-18

1997-04-18 Application filed by ALGENE BIOTECHNOLOGIES filed Critical ALGENE BIOTECHNOLOGIES

1997-04-18 Priority to CA 2203085 priority Critical patent/CA2203085A1/fr

1998-10-18 Publication of CA2203085A1 publication Critical patent/CA2203085A1/fr

Status Abandoned legal-status Critical Current

Links

208000024827 Alzheimer disease Diseases 0.000 title abstract description 27
108090000623 proteins and genes Proteins 0.000 claims abstract description 80
210000000349 chromosome Anatomy 0.000 claims description 16
230000037361 pathway Effects 0.000 claims description 11
239000003550 marker Substances 0.000 claims description 9
108091092878 Microsatellite Proteins 0.000 claims description 7
238000003745 diagnosis Methods 0.000 claims description 7
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 claims description 4
108020004098 protein phosphatase inhibitor-2 Proteins 0.000 claims description 4
102100037976 Protein phosphatase inhibitor 2 Human genes 0.000 claims description 2
101150084750 1 gene Proteins 0.000 claims 4
102000004169 proteins and genes Human genes 0.000 abstract description 20
238000000034 method Methods 0.000 abstract description 18
108020004707 nucleic acids Proteins 0.000 abstract description 13
102000039446 nucleic acids Human genes 0.000 abstract description 13
150000007523 nucleic acids Chemical class 0.000 abstract description 13
206010015037 epilepsy Diseases 0.000 abstract description 8
208000015114 central nervous system disease Diseases 0.000 abstract description 6
230000014509 gene expression Effects 0.000 abstract description 5
239000013598 vector Substances 0.000 abstract description 3
241000282412 Homo Species 0.000 abstract description 2
238000001514 detection method Methods 0.000 abstract description 2
101150010487 are gene Proteins 0.000 abstract 1
238000004458 analytical method Methods 0.000 description 16
230000002068 genetic effect Effects 0.000 description 16
230000035772 mutation Effects 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
108020004414 DNA Proteins 0.000 description 13
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 13
208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 13
229960000367 inositol Drugs 0.000 description 13
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 13
208000015756 familial Alzheimer disease Diseases 0.000 description 12
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 12
239000000523 sample Substances 0.000 description 12
108700028369 Alleles Proteins 0.000 description 11
201000010099 disease Diseases 0.000 description 11
101710095339 Apolipoprotein E Proteins 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
238000013507 mapping Methods 0.000 description 7
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 6
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 6
102100029470 Apolipoprotein E Human genes 0.000 description 6
108700024394 Exon Proteins 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 5
206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 5
108010036933 Presenilin-1 Proteins 0.000 description 5
102100022033 Presenilin-1 Human genes 0.000 description 5
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
238000010367 cloning Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 description 5
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000006870 function Effects 0.000 description 4
238000012252 genetic analysis Methods 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
238000012216 screening Methods 0.000 description 4
208000037259 Amyloid Plaque Diseases 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
101150089079 PS1 gene Proteins 0.000 description 3
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
235000015107 ale Nutrition 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
102000054766 genetic haplotypes Human genes 0.000 description 3
238000002372 labelling Methods 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000011664 signaling Effects 0.000 description 3
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
102000013918 Apolipoproteins E Human genes 0.000 description 2
108010025628 Apolipoproteins E Proteins 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
101000975428 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 1 Proteins 0.000 description 2
102100024039 Inositol 1,4,5-trisphosphate receptor type 1 Human genes 0.000 description 2
238000007476 Maximum Likelihood Methods 0.000 description 2
101150023107 PS2 gene Proteins 0.000 description 2
108010050254 Presenilins Proteins 0.000 description 2
102000015499 Presenilins Human genes 0.000 description 2
102000014384 Type C Phospholipases Human genes 0.000 description 2
108010079194 Type C Phospholipases Proteins 0.000 description 2
230000004075 alteration Effects 0.000 description 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
101150031224 app gene Proteins 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
230000004927 fusion Effects 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
208000010194 infantile onset spinocerebellar ataxia Diseases 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
201000011561 mitochondrial DNA depletion syndrome 7 Diseases 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
239000002243 precursor Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
101150090724 3 gene Proteins 0.000 description 1
108010078523 APP717 Proteins 0.000 description 1
208000022099 Alzheimer disease 2 Diseases 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
241000736839 Chara Species 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
206010008635 Cholestasis Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
101100234002 Drosophila melanogaster Shal gene Proteins 0.000 description 1
101150013191 E gene Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241001131639 Eurystomus orientalis Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
208000034308 Grand mal convulsion Diseases 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
101000975401 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 3 Proteins 0.000 description 1
208000035795 Hypocalcemic vitamin D-dependent rickets Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 1
102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
102100024035 Inositol 1,4,5-trisphosphate receptor type 3 Human genes 0.000 description 1
-1 Iucirerase Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010068871 Myotonic dystrophy Diseases 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
102000017343 Phosphatidylinositol kinases Human genes 0.000 description 1
108050005377 Phosphatidylinositol kinases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
241000269435 Rana <genus> Species 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000905510 Scena Species 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
244000166071 Shorea robusta Species 0.000 description 1
235000015076 Shorea robusta Nutrition 0.000 description 1
241000364027 Sinoe Species 0.000 description 1
208000037140 Steinert myotonic dystrophy Diseases 0.000 description 1
102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
206010043994 Tonic convulsion Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000003925 brain function Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000007870 cholestasis Effects 0.000 description 1
231100000359 cholestasis Toxicity 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000001879 hippocampal ca1 region Anatomy 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
208000021005 inheritance pattern Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
150000002611 lead compounds Chemical class 0.000 description 1
210000004558 lewy body Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003274 myotonic effect Effects 0.000 description 1
210000002682 neurofibrillary tangle Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
210000000449 purkinje cell Anatomy 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
208000007442 rickets Diseases 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000003478 temporal lobe Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
208000033584 type 1 vitamin D-dependent rickets Diseases 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pathology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Immunology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA 2203085 1997-04-18 1997-04-18 5-phosphatase de type ii et son role dans la maladie d'alzheimer Abandoned CA2203085A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2203085 CA2203085A1 (fr)	1997-04-18	1997-04-18	5-phosphatase de type ii et son role dans la maladie d'alzheimer

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2203085 CA2203085A1 (fr)	1997-04-18	1997-04-18	5-phosphatase de type ii et son role dans la maladie d'alzheimer

Publications (1)

Publication Number	Publication Date
CA2203085A1 true CA2203085A1 (fr)	1998-10-18

Family

ID=4160472

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2203085 Abandoned CA2203085A1 (fr)	1997-04-18	1997-04-18	5-phosphatase de type ii et son role dans la maladie d'alzheimer

Country Status (1)

Country	Link
CA (1)	CA2203085A1 (fr)

1997
- 1997-04-18 CA CA 2203085 patent/CA2203085A1/fr not_active Abandoned

Publication	Publication Date	Title
Lendon et al.	1997	E280A PS‐1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles
US7033752B1 (en)	2006-04-25	Spinal muscular atrophy diagnostic methods
Nacmias et al.	1995	ApoE genotype and familial Alzheimer's disease: a possible influence on age of onset in APP717 Val→ Ile mutated families
US20160177393A1 (en)	2016-06-23	Lafora's disease gene
EP0970243B1 (fr)	2006-01-04	Diagnostic et traitement de glaucome
EP0711833B1 (fr)	2005-08-03	Gène de survie des neurones moteurs: gène de l'atrophie musculaire spinale
CA2226658A1 (fr)	1997-01-30	Gene et produits geniques de la maladie d'alzheimer precoce
US7108975B2 (en)	2006-09-19	Atlastin
Wang et al.	1997	Extensive DNA deletion associated with severe disease alleles on spinal muscular atrophy homologues
CA2203085A1 (fr)	1998-10-18	5-phosphatase de type ii et son role dans la maladie d'alzheimer
AU2006225995B2 (en)	2011-03-17	Human autism susceptibility gene encoding a transmembrane protein and uses thereof
KR102168332B1 (ko)	2020-10-21	망막색소변성증의 진단에 이용 가능한 15개의 ush2a 유전자 돌연변이체 및 이외 용도
CA2203071A1 (fr)	1998-10-18	Gene du chromosome 10 et produits genetiques associes a la maladie d'alzheimer
CA2203070A1 (fr)	1998-10-18	Gene du chromosome 6 et produits genetiques associes a la maladie d'alzheimer
CA2203069A1 (fr)	1998-10-18	Gene du chromosome 12 et produits genetiques associes a la maladie d'alzheimer
JP2000511408A (ja)	2000-09-05	新規治療
CA2203068A1 (fr)	1998-10-18	Gene du chromosome 1p et produits genetiques associes a la maladie d'alzheimer
US5830661A (en)	1998-11-03	Diagnosis and treatment of glaucoma
US20090215065A1 (en)	2009-08-27	Atlastin
CA2203083A1 (fr)	1998-10-18	Gene et adnc intervenant dans la maladie d'alzheimer
CA2203084A1 (fr)	1998-10-18	Voie des phosphates d'inositol et leur role dans la maladie d'alzheimer
CA2203072A1 (fr)	1998-10-18	Marqueurs chromosomiques associes a la maladie d'alzheimer
US6432635B1 (en)	2002-08-13	Cystatin B mutants
Van Broeckhoven	1994	Genes in early onset Alzheimer's disease: implications for AD research
WO2002027022A2 (fr)	2002-04-04	Ameliorations relatives aux traitements de maladie des yeux

Legal Events

Date	Code	Title	Description
1999-07-21	FZDE	Dead